APOC3 and Thrombocytopenia: A galactosamine-conjugated apolipoprotein C-III antisense oligonucleotide analogue (olezarcen) is currently under investigation in a Phase III trial that targets ApoC3 mRNA in hepatocytes and has shown similar TG reduction at lower doses, therefore mitigating drug-specific side effects, and the thrombocytopenia experienced with volanesorsen [134].